MY KOLKATA EDUGRAPH
ADVERTISEMENT
regular-article-logo Sunday, 24 November 2024

Need to create environment to quickly scale up vaccine production, says Goyal

'World not producing sufficient jabs due to limited licensing agreements'

Our Bureau, Agencies New Delhi Published 15.04.21, 03:24 PM
Piyush Goyal

Piyush Goyal File picture

There is a need to create environment for quick scaling up of global production of vaccines and other medical products to contain the spread of coronavirus and this requires temporary removal of all hurdles, including related with intellectual property protection in the WTO, Commerce and Industry Minister Piyush Goyal has said.

ADVERTISEMENT

In this regard, he said, India and South Africa along with 57 other WTO (World Trade Organisation) members have co-sponsored a proposal for temporary and limited-scope waiver from certain provisions of the TRIPS (trade related aspects of intellectual property rights) agreement relevant to the prevention, treatment and containment of COVID-19.

Goyal said that this waiver is not intended to take away protection given to pharma companies, and it focuses only on COVID-19 vaccines, associated medicines, and cure.

"We need to create an environment for quick scaling up of global production, not only for vaccines but also other medical products, such as therapeutics and diagnostics. This requires temporary removal of all impediments to the production of COVID-19 medical products, including where necessary Intellectual Property protection," he has said.

The minister was speaking at a WTO event -- COVID-19 And Vaccine Equity: What Can The WTO Contribute? -- on April 14.

The minister stated that the world is not producing sufficient vaccines due to limited licensing agreements.

To bridge the supply deficit, every tool at our disposal should be used towards producing enough vaccines, he said adding all initiatives must be explored in parallel and in a timely manner to ramp up manufacturing of COVID-19 medical products.

Goyal said that every country should strive for resilient supply chains by ensuring unimpeded access to raw materials required for COVID-19 products and failure to do so could prolong the pandemic for many years through cycles of mutation and may cost the global economy trillions of dollars.

"The time to act is now," he added.

Follow us on:
ADVERTISEMENT
ADVERTISEMENT